What is the brand name of methotrexate?

A. Edema is typically managed with diuretic agents that inhibit sodium reabsorption in the renal tubules. Hydroxyzine is an H1-receptor antagonist and does not possess the pharmacological properties required to mobilize interstitial fluid. It is not an FDA-approved treatment for edema.

B. Status asthmaticus is a life-threatening medical emergency requiring systemic corticosteroids and bronchodilators. Hydroxyzine is contraindicated in early pregnancy and not indicated for acute respiratory distress. It lacks the beta-2 adrenergic agonist activity necessary to reverse severe bronchospasm in asthma.

C. Pruritus due to histamine-mediated reactions is a primary FDA-approved indication for hydroxyzine. As a first-generation antihistamine, it competitively blocks H1 receptors to alleviate itching associated with dermatological conditions. It is specifically indicated for allergic conditions such as chronic urticaria.

D. Anxiety is an FDA-approved labeled indication for hydroxyzine hydrochloride. It exerts anxiolytic effects by acting as an antagonist at the 5-HT2A serotonin receptor and H1 receptors in the central nervous system. This results in significant sedative and calming properties.

A. Montelukast sodium is classified as a leukotriene receptor antagonist. It selectively binds to cysteinyl leukotriene type 1 receptors to inhibit physiological effects of leukotrienes. This prevents airway edema, smooth muscle contraction, and inflammatory responses in asthma and allergic rhinitis.

B. This agent is not a primary COPD agent as it does not sufficiently address the fixed airflow obstruction or chronic bronchitis characteristic of that disease. While it has antiallergy properties, it is not indicated as a first-line treatment for COPD.

C. While montelukast is an antiasthmatic, it is not FDA-approved as a primary COPD agent. Guidelines for chronic obstructive pulmonary disease prioritize long-acting bronchodilators and muscarinic antagonists over leukotriene modifiers. It lacks efficacy in treating non-allergic chronic obstructive lung pathologies.

D. Montelukast is an antiallergy medication, but it possesses no antiviral activity. It does not inhibit viral replication, entry, or protein synthesis within host cells. It is exclusively used for managing inflammatory airway diseases and is never indicated for viral infections.